This latter group of patients showed a trend towards an incremental benefit from ICI therapy as compared to patients treated for recurrent HCC, although this difference in treatment benefit should be considered in the risk/benefit analysis.
← all excerpts
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.
1
—
—